Journal of Cachexia Sarcopenia and Muscle-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1194253, encodeId=831c119425333, content=这个返修后多久会under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Feb 16 23:20:38 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164604, encodeId=f6e5216460404, content=偏重的研究方向：肌肉减少症;临床 经验分享：四月中旬投稿，好像是三个月后开始under review，十月底了，还是under review，无语住了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d46c84771, createdName=Jake, createdTime=Tue Oct 24 12:26:40 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=913051, encodeId=fb0d913051a4, content=偏重的研究方向：老年医学 经验分享：编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Sat Jan 02 12:14:55 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163244, encodeId=081021632447b, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肌少症;TI PS 经验分享：10.11投，6天过去了还是Submitted to Journal，一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77b58371430, createdName=ms4000001972100444, createdTime=Tue Oct 17 10:00:06 CST 2023, time=2023-10-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2121522, encodeId=a64a212152295, content=投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f3d5450988, createdName=ms5000001623040389, createdTime=Fri Mar 24 09:44:51 CST 2023, time=2023-03-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=886131, encodeId=71b588613196, content=自引率太高，很危险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200917/bb23a74f9c744d179d270412c59f17d2/d9f27255e9a4472e9182ae4cebc04cd3.JPG, createdBy=d0705419106, createdName=ms9329439854812607, createdTime=Thu Sep 17 18:00:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546043, encodeId=3ea254604349, content=刚中一篇.投稿.大修拒稿.2人.每个20条意见. 半年后再投.再大修.2个专业REVIEWER,又是每人10多条comments.回复意见堪比论文长度. 修回后.一个月返回.小修. 两个REVIEWER.几条意见.特别难回答. 再修回.还是送外审.一个月回复. ACCEPT., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=319, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83err4ElTHaq5qoSdGhtKstFQiaP37oDBlkk2hzs3eM47TEmic45FibPcaicHypicBAdzicSrXvkFqV2icoFOQ/132, createdBy=da4d6227, createdName=fullcol, createdTime=Tue Aug 29 15:04:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101111, encodeId=0d52210111145, content=审稿速度:6.0 | 投稿命中率:5.0 经验分享：等了6个月，两个审稿人，一个没有很大的意见，一个大修补实验，编辑直接拒了，一生黑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23963113360, createdName=2516249429, createdTime=Thu Nov 17 14:52:18 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105519, encodeId=365311055194e, content=引言和讨论的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105520, encodeId=9554110552047, content=怎么撰写引言？区别于讨论？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2022-02-16 ms2000001542264371

这个返修后多久会under review？

99 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=1194253, encodeId=831c119425333, content=这个返修后多久会under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Feb 16 23:20:38 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164604, encodeId=f6e5216460404, content=偏重的研究方向：肌肉减少症;临床 经验分享：四月中旬投稿，好像是三个月后开始under review，十月底了，还是under review，无语住了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d46c84771, createdName=Jake, createdTime=Tue Oct 24 12:26:40 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=913051, encodeId=fb0d913051a4, content=偏重的研究方向：老年医学 经验分享：编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Sat Jan 02 12:14:55 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163244, encodeId=081021632447b, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肌少症;TI PS 经验分享：10.11投，6天过去了还是Submitted to Journal，一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77b58371430, createdName=ms4000001972100444, createdTime=Tue Oct 17 10:00:06 CST 2023, time=2023-10-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2121522, encodeId=a64a212152295, content=投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f3d5450988, createdName=ms5000001623040389, createdTime=Fri Mar 24 09:44:51 CST 2023, time=2023-03-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=886131, encodeId=71b588613196, content=自引率太高，很危险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200917/bb23a74f9c744d179d270412c59f17d2/d9f27255e9a4472e9182ae4cebc04cd3.JPG, createdBy=d0705419106, createdName=ms9329439854812607, createdTime=Thu Sep 17 18:00:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546043, encodeId=3ea254604349, content=刚中一篇.投稿.大修拒稿.2人.每个20条意见. 半年后再投.再大修.2个专业REVIEWER,又是每人10多条comments.回复意见堪比论文长度. 修回后.一个月返回.小修. 两个REVIEWER.几条意见.特别难回答. 再修回.还是送外审.一个月回复. ACCEPT., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=319, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83err4ElTHaq5qoSdGhtKstFQiaP37oDBlkk2hzs3eM47TEmic45FibPcaicHypicBAdzicSrXvkFqV2icoFOQ/132, createdBy=da4d6227, createdName=fullcol, createdTime=Tue Aug 29 15:04:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101111, encodeId=0d52210111145, content=审稿速度:6.0 | 投稿命中率:5.0 经验分享：等了6个月，两个审稿人，一个没有很大的意见，一个大修补实验，编辑直接拒了，一生黑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23963113360, createdName=2516249429, createdTime=Thu Nov 17 14:52:18 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105519, encodeId=365311055194e, content=引言和讨论的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105520, encodeId=9554110552047, content=怎么撰写引言？区别于讨论？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-10-24 Jake 来自浙江省

偏重的研究方向：肌肉减少症;临床
经验分享：四月中旬投稿，好像是三个月后开始under review，十月底了，还是under review，无语住了！

33 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1194253, encodeId=831c119425333, content=这个返修后多久会under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Feb 16 23:20:38 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164604, encodeId=f6e5216460404, content=偏重的研究方向：肌肉减少症;临床 经验分享：四月中旬投稿，好像是三个月后开始under review，十月底了，还是under review，无语住了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d46c84771, createdName=Jake, createdTime=Tue Oct 24 12:26:40 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=913051, encodeId=fb0d913051a4, content=偏重的研究方向：老年医学 经验分享：编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Sat Jan 02 12:14:55 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163244, encodeId=081021632447b, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肌少症;TI PS 经验分享：10.11投，6天过去了还是Submitted to Journal，一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77b58371430, createdName=ms4000001972100444, createdTime=Tue Oct 17 10:00:06 CST 2023, time=2023-10-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2121522, encodeId=a64a212152295, content=投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f3d5450988, createdName=ms5000001623040389, createdTime=Fri Mar 24 09:44:51 CST 2023, time=2023-03-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=886131, encodeId=71b588613196, content=自引率太高，很危险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200917/bb23a74f9c744d179d270412c59f17d2/d9f27255e9a4472e9182ae4cebc04cd3.JPG, createdBy=d0705419106, createdName=ms9329439854812607, createdTime=Thu Sep 17 18:00:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546043, encodeId=3ea254604349, content=刚中一篇.投稿.大修拒稿.2人.每个20条意见. 半年后再投.再大修.2个专业REVIEWER,又是每人10多条comments.回复意见堪比论文长度. 修回后.一个月返回.小修. 两个REVIEWER.几条意见.特别难回答. 再修回.还是送外审.一个月回复. ACCEPT., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=319, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83err4ElTHaq5qoSdGhtKstFQiaP37oDBlkk2hzs3eM47TEmic45FibPcaicHypicBAdzicSrXvkFqV2icoFOQ/132, createdBy=da4d6227, createdName=fullcol, createdTime=Tue Aug 29 15:04:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101111, encodeId=0d52210111145, content=审稿速度:6.0 | 投稿命中率:5.0 经验分享：等了6个月，两个审稿人，一个没有很大的意见，一个大修补实验，编辑直接拒了，一生黑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23963113360, createdName=2516249429, createdTime=Thu Nov 17 14:52:18 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105519, encodeId=365311055194e, content=引言和讨论的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105520, encodeId=9554110552047, content=怎么撰写引言？区别于讨论？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-01-02 ms9000001982912997

偏重的研究方向：老年医学
经验分享：编辑很友好

74 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1194253, encodeId=831c119425333, content=这个返修后多久会under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Feb 16 23:20:38 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164604, encodeId=f6e5216460404, content=偏重的研究方向：肌肉减少症;临床 经验分享：四月中旬投稿，好像是三个月后开始under review，十月底了，还是under review，无语住了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d46c84771, createdName=Jake, createdTime=Tue Oct 24 12:26:40 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=913051, encodeId=fb0d913051a4, content=偏重的研究方向：老年医学 经验分享：编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Sat Jan 02 12:14:55 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163244, encodeId=081021632447b, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肌少症;TI PS 经验分享：10.11投，6天过去了还是Submitted to Journal，一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77b58371430, createdName=ms4000001972100444, createdTime=Tue Oct 17 10:00:06 CST 2023, time=2023-10-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2121522, encodeId=a64a212152295, content=投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f3d5450988, createdName=ms5000001623040389, createdTime=Fri Mar 24 09:44:51 CST 2023, time=2023-03-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=886131, encodeId=71b588613196, content=自引率太高，很危险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200917/bb23a74f9c744d179d270412c59f17d2/d9f27255e9a4472e9182ae4cebc04cd3.JPG, createdBy=d0705419106, createdName=ms9329439854812607, createdTime=Thu Sep 17 18:00:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546043, encodeId=3ea254604349, content=刚中一篇.投稿.大修拒稿.2人.每个20条意见. 半年后再投.再大修.2个专业REVIEWER,又是每人10多条comments.回复意见堪比论文长度. 修回后.一个月返回.小修. 两个REVIEWER.几条意见.特别难回答. 再修回.还是送外审.一个月回复. ACCEPT., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=319, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83err4ElTHaq5qoSdGhtKstFQiaP37oDBlkk2hzs3eM47TEmic45FibPcaicHypicBAdzicSrXvkFqV2icoFOQ/132, createdBy=da4d6227, createdName=fullcol, createdTime=Tue Aug 29 15:04:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101111, encodeId=0d52210111145, content=审稿速度:6.0 | 投稿命中率:5.0 经验分享：等了6个月，两个审稿人，一个没有很大的意见，一个大修补实验，编辑直接拒了，一生黑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23963113360, createdName=2516249429, createdTime=Thu Nov 17 14:52:18 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105519, encodeId=365311055194e, content=引言和讨论的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105520, encodeId=9554110552047, content=怎么撰写引言？区别于讨论？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-10-17 ms4000001972100444 来自安徽省

审稿速度:24.0 | 投稿命中率:25.0
偏重的研究方向：肌少症;TI PS
经验分享：10.11投，6天过去了还是Submitted to Journal，一般要等多久啊

20 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1194253, encodeId=831c119425333, content=这个返修后多久会under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Feb 16 23:20:38 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164604, encodeId=f6e5216460404, content=偏重的研究方向：肌肉减少症;临床 经验分享：四月中旬投稿，好像是三个月后开始under review，十月底了，还是under review，无语住了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d46c84771, createdName=Jake, createdTime=Tue Oct 24 12:26:40 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=913051, encodeId=fb0d913051a4, content=偏重的研究方向：老年医学 经验分享：编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Sat Jan 02 12:14:55 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163244, encodeId=081021632447b, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肌少症;TI PS 经验分享：10.11投，6天过去了还是Submitted to Journal，一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77b58371430, createdName=ms4000001972100444, createdTime=Tue Oct 17 10:00:06 CST 2023, time=2023-10-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2121522, encodeId=a64a212152295, content=投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f3d5450988, createdName=ms5000001623040389, createdTime=Fri Mar 24 09:44:51 CST 2023, time=2023-03-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=886131, encodeId=71b588613196, content=自引率太高，很危险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200917/bb23a74f9c744d179d270412c59f17d2/d9f27255e9a4472e9182ae4cebc04cd3.JPG, createdBy=d0705419106, createdName=ms9329439854812607, createdTime=Thu Sep 17 18:00:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546043, encodeId=3ea254604349, content=刚中一篇.投稿.大修拒稿.2人.每个20条意见. 半年后再投.再大修.2个专业REVIEWER,又是每人10多条comments.回复意见堪比论文长度. 修回后.一个月返回.小修. 两个REVIEWER.几条意见.特别难回答. 再修回.还是送外审.一个月回复. ACCEPT., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=319, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83err4ElTHaq5qoSdGhtKstFQiaP37oDBlkk2hzs3eM47TEmic45FibPcaicHypicBAdzicSrXvkFqV2icoFOQ/132, createdBy=da4d6227, createdName=fullcol, createdTime=Tue Aug 29 15:04:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101111, encodeId=0d52210111145, content=审稿速度:6.0 | 投稿命中率:5.0 经验分享：等了6个月，两个审稿人，一个没有很大的意见，一个大修补实验，编辑直接拒了，一生黑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23963113360, createdName=2516249429, createdTime=Thu Nov 17 14:52:18 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105519, encodeId=365311055194e, content=引言和讨论的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105520, encodeId=9554110552047, content=怎么撰写引言？区别于讨论？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-03-24 ms5000001623040389 来自四川省

投稿中

38 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1194253, encodeId=831c119425333, content=这个返修后多久会under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Feb 16 23:20:38 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164604, encodeId=f6e5216460404, content=偏重的研究方向：肌肉减少症;临床 经验分享：四月中旬投稿，好像是三个月后开始under review，十月底了，还是under review，无语住了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d46c84771, createdName=Jake, createdTime=Tue Oct 24 12:26:40 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=913051, encodeId=fb0d913051a4, content=偏重的研究方向：老年医学 经验分享：编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Sat Jan 02 12:14:55 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163244, encodeId=081021632447b, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肌少症;TI PS 经验分享：10.11投，6天过去了还是Submitted to Journal，一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77b58371430, createdName=ms4000001972100444, createdTime=Tue Oct 17 10:00:06 CST 2023, time=2023-10-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2121522, encodeId=a64a212152295, content=投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f3d5450988, createdName=ms5000001623040389, createdTime=Fri Mar 24 09:44:51 CST 2023, time=2023-03-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=886131, encodeId=71b588613196, content=自引率太高，很危险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200917/bb23a74f9c744d179d270412c59f17d2/d9f27255e9a4472e9182ae4cebc04cd3.JPG, createdBy=d0705419106, createdName=ms9329439854812607, createdTime=Thu Sep 17 18:00:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546043, encodeId=3ea254604349, content=刚中一篇.投稿.大修拒稿.2人.每个20条意见. 半年后再投.再大修.2个专业REVIEWER,又是每人10多条comments.回复意见堪比论文长度. 修回后.一个月返回.小修. 两个REVIEWER.几条意见.特别难回答. 再修回.还是送外审.一个月回复. ACCEPT., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=319, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83err4ElTHaq5qoSdGhtKstFQiaP37oDBlkk2hzs3eM47TEmic45FibPcaicHypicBAdzicSrXvkFqV2icoFOQ/132, createdBy=da4d6227, createdName=fullcol, createdTime=Tue Aug 29 15:04:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101111, encodeId=0d52210111145, content=审稿速度:6.0 | 投稿命中率:5.0 经验分享：等了6个月，两个审稿人，一个没有很大的意见，一个大修补实验，编辑直接拒了，一生黑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23963113360, createdName=2516249429, createdTime=Thu Nov 17 14:52:18 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105519, encodeId=365311055194e, content=引言和讨论的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105520, encodeId=9554110552047, content=怎么撰写引言？区别于讨论？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2020-09-17 ms9329439854812607

自引率太高，很危险

197 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1194253, encodeId=831c119425333, content=这个返修后多久会under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Feb 16 23:20:38 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164604, encodeId=f6e5216460404, content=偏重的研究方向：肌肉减少症;临床 经验分享：四月中旬投稿，好像是三个月后开始under review，十月底了，还是under review，无语住了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d46c84771, createdName=Jake, createdTime=Tue Oct 24 12:26:40 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=913051, encodeId=fb0d913051a4, content=偏重的研究方向：老年医学 经验分享：编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Sat Jan 02 12:14:55 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163244, encodeId=081021632447b, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肌少症;TI PS 经验分享：10.11投，6天过去了还是Submitted to Journal，一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77b58371430, createdName=ms4000001972100444, createdTime=Tue Oct 17 10:00:06 CST 2023, time=2023-10-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2121522, encodeId=a64a212152295, content=投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f3d5450988, createdName=ms5000001623040389, createdTime=Fri Mar 24 09:44:51 CST 2023, time=2023-03-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=886131, encodeId=71b588613196, content=自引率太高，很危险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200917/bb23a74f9c744d179d270412c59f17d2/d9f27255e9a4472e9182ae4cebc04cd3.JPG, createdBy=d0705419106, createdName=ms9329439854812607, createdTime=Thu Sep 17 18:00:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546043, encodeId=3ea254604349, content=刚中一篇.投稿.大修拒稿.2人.每个20条意见. 半年后再投.再大修.2个专业REVIEWER,又是每人10多条comments.回复意见堪比论文长度. 修回后.一个月返回.小修. 两个REVIEWER.几条意见.特别难回答. 再修回.还是送外审.一个月回复. ACCEPT., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=319, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83err4ElTHaq5qoSdGhtKstFQiaP37oDBlkk2hzs3eM47TEmic45FibPcaicHypicBAdzicSrXvkFqV2icoFOQ/132, createdBy=da4d6227, createdName=fullcol, createdTime=Tue Aug 29 15:04:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101111, encodeId=0d52210111145, content=审稿速度:6.0 | 投稿命中率:5.0 经验分享：等了6个月，两个审稿人，一个没有很大的意见，一个大修补实验，编辑直接拒了，一生黑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23963113360, createdName=2516249429, createdTime=Thu Nov 17 14:52:18 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105519, encodeId=365311055194e, content=引言和讨论的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105520, encodeId=9554110552047, content=怎么撰写引言？区别于讨论？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2017-08-29 fullcol

刚中一篇.投稿.大修拒稿.2人.每个20条意见. 半年后再投.再大修.2个专业REVIEWER,又是每人10多条comments.回复意见堪比论文长度. 修回后.一个月返回.小修. 两个REVIEWER.几条意见.特别难回答. 再修回.还是送外审.一个月回复. ACCEPT.

319 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1194253, encodeId=831c119425333, content=这个返修后多久会under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Feb 16 23:20:38 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164604, encodeId=f6e5216460404, content=偏重的研究方向：肌肉减少症;临床 经验分享：四月中旬投稿，好像是三个月后开始under review，十月底了，还是under review，无语住了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d46c84771, createdName=Jake, createdTime=Tue Oct 24 12:26:40 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=913051, encodeId=fb0d913051a4, content=偏重的研究方向：老年医学 经验分享：编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Sat Jan 02 12:14:55 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163244, encodeId=081021632447b, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肌少症;TI PS 经验分享：10.11投，6天过去了还是Submitted to Journal，一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77b58371430, createdName=ms4000001972100444, createdTime=Tue Oct 17 10:00:06 CST 2023, time=2023-10-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2121522, encodeId=a64a212152295, content=投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f3d5450988, createdName=ms5000001623040389, createdTime=Fri Mar 24 09:44:51 CST 2023, time=2023-03-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=886131, encodeId=71b588613196, content=自引率太高，很危险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200917/bb23a74f9c744d179d270412c59f17d2/d9f27255e9a4472e9182ae4cebc04cd3.JPG, createdBy=d0705419106, createdName=ms9329439854812607, createdTime=Thu Sep 17 18:00:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546043, encodeId=3ea254604349, content=刚中一篇.投稿.大修拒稿.2人.每个20条意见. 半年后再投.再大修.2个专业REVIEWER,又是每人10多条comments.回复意见堪比论文长度. 修回后.一个月返回.小修. 两个REVIEWER.几条意见.特别难回答. 再修回.还是送外审.一个月回复. ACCEPT., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=319, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83err4ElTHaq5qoSdGhtKstFQiaP37oDBlkk2hzs3eM47TEmic45FibPcaicHypicBAdzicSrXvkFqV2icoFOQ/132, createdBy=da4d6227, createdName=fullcol, createdTime=Tue Aug 29 15:04:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101111, encodeId=0d52210111145, content=审稿速度:6.0 | 投稿命中率:5.0 经验分享：等了6个月，两个审稿人，一个没有很大的意见，一个大修补实验，编辑直接拒了，一生黑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23963113360, createdName=2516249429, createdTime=Thu Nov 17 14:52:18 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105519, encodeId=365311055194e, content=引言和讨论的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105520, encodeId=9554110552047, content=怎么撰写引言？区别于讨论？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2022-11-17 2516249429

审稿速度:6.0 | 投稿命中率:5.0
经验分享：等了6个月，两个审稿人，一个没有很大的意见，一个大修补实验，编辑直接拒了，一生黑

37 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1194253, encodeId=831c119425333, content=这个返修后多久会under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Feb 16 23:20:38 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164604, encodeId=f6e5216460404, content=偏重的研究方向：肌肉减少症;临床 经验分享：四月中旬投稿，好像是三个月后开始under review，十月底了，还是under review，无语住了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d46c84771, createdName=Jake, createdTime=Tue Oct 24 12:26:40 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=913051, encodeId=fb0d913051a4, content=偏重的研究方向：老年医学 经验分享：编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Sat Jan 02 12:14:55 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163244, encodeId=081021632447b, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肌少症;TI PS 经验分享：10.11投，6天过去了还是Submitted to Journal，一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77b58371430, createdName=ms4000001972100444, createdTime=Tue Oct 17 10:00:06 CST 2023, time=2023-10-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2121522, encodeId=a64a212152295, content=投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f3d5450988, createdName=ms5000001623040389, createdTime=Fri Mar 24 09:44:51 CST 2023, time=2023-03-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=886131, encodeId=71b588613196, content=自引率太高，很危险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200917/bb23a74f9c744d179d270412c59f17d2/d9f27255e9a4472e9182ae4cebc04cd3.JPG, createdBy=d0705419106, createdName=ms9329439854812607, createdTime=Thu Sep 17 18:00:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546043, encodeId=3ea254604349, content=刚中一篇.投稿.大修拒稿.2人.每个20条意见. 半年后再投.再大修.2个专业REVIEWER,又是每人10多条comments.回复意见堪比论文长度. 修回后.一个月返回.小修. 两个REVIEWER.几条意见.特别难回答. 再修回.还是送外审.一个月回复. ACCEPT., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=319, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83err4ElTHaq5qoSdGhtKstFQiaP37oDBlkk2hzs3eM47TEmic45FibPcaicHypicBAdzicSrXvkFqV2icoFOQ/132, createdBy=da4d6227, createdName=fullcol, createdTime=Tue Aug 29 15:04:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101111, encodeId=0d52210111145, content=审稿速度:6.0 | 投稿命中率:5.0 经验分享：等了6个月，两个审稿人，一个没有很大的意见，一个大修补实验，编辑直接拒了，一生黑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23963113360, createdName=2516249429, createdTime=Thu Nov 17 14:52:18 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105519, encodeId=365311055194e, content=引言和讨论的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105520, encodeId=9554110552047, content=怎么撰写引言？区别于讨论？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-12-28 Gym璨烨

引言和讨论的区别？

63 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1194253, encodeId=831c119425333, content=这个返修后多久会under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0ee5612681, createdName=ms2000001542264371, createdTime=Wed Feb 16 23:20:38 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2164604, encodeId=f6e5216460404, content=偏重的研究方向：肌肉减少症;临床 经验分享：四月中旬投稿，好像是三个月后开始under review，十月底了，还是under review，无语住了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d46c84771, createdName=Jake, createdTime=Tue Oct 24 12:26:40 CST 2023, time=2023-10-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=913051, encodeId=fb0d913051a4, content=偏重的研究方向：老年医学 经验分享：编辑很友好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bda35414315, createdName=ms9000001982912997, createdTime=Sat Jan 02 12:14:55 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163244, encodeId=081021632447b, content=审稿速度:24.0 | 投稿命中率:25.0 偏重的研究方向：肌少症;TI PS 经验分享：10.11投，6天过去了还是Submitted to Journal，一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77b58371430, createdName=ms4000001972100444, createdTime=Tue Oct 17 10:00:06 CST 2023, time=2023-10-17, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2121522, encodeId=a64a212152295, content=投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f3d5450988, createdName=ms5000001623040389, createdTime=Fri Mar 24 09:44:51 CST 2023, time=2023-03-24, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=886131, encodeId=71b588613196, content=自引率太高，很危险, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200917/bb23a74f9c744d179d270412c59f17d2/d9f27255e9a4472e9182ae4cebc04cd3.JPG, createdBy=d0705419106, createdName=ms9329439854812607, createdTime=Thu Sep 17 18:00:15 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546043, encodeId=3ea254604349, content=刚中一篇.投稿.大修拒稿.2人.每个20条意见. 半年后再投.再大修.2个专业REVIEWER,又是每人10多条comments.回复意见堪比论文长度. 修回后.一个月返回.小修. 两个REVIEWER.几条意见.特别难回答. 再修回.还是送外审.一个月回复. ACCEPT., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=319, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83err4ElTHaq5qoSdGhtKstFQiaP37oDBlkk2hzs3eM47TEmic45FibPcaicHypicBAdzicSrXvkFqV2icoFOQ/132, createdBy=da4d6227, createdName=fullcol, createdTime=Tue Aug 29 15:04:00 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101111, encodeId=0d52210111145, content=审稿速度:6.0 | 投稿命中率:5.0 经验分享：等了6个月，两个审稿人，一个没有很大的意见，一个大修补实验，编辑直接拒了，一生黑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=23963113360, createdName=2516249429, createdTime=Thu Nov 17 14:52:18 CST 2022, time=2022-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105519, encodeId=365311055194e, content=引言和讨论的区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105520, encodeId=9554110552047, content=怎么撰写引言？区别于讨论？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-12-28 msSSSSSD

怎么撰写引言？区别于讨论？

0 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务